Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 410Lung Neoplasms 261Small Cell Lung Carcinoma 75Colorectal Neoplasms 71Breast Neoplasms 52Ovarian Neoplasms 48Neoplasms 48Melanoma 48Pancreatic Neoplasms 45Neoplasm Metastasis 38Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 31Prostatic Neoplasms 28Head and Neck Neoplasms 27Esophageal Neoplasms 26Carcinoma, Renal Cell 26Endometrial Neoplasms 25Colonic Neoplasms 24Triple Negative Breast Neoplasms 23Uterine Cervical Neoplasms 22Urinary Bladder Neoplasms 21Carcinoma, Hepatocellular 21Mesothelioma, Malignant 14Mesothelioma 14Sarcoma 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Lung Diseases 13Liver Neoplasms 13Carcinoma, Transitional Cell 13Thyroid Neoplasms 12

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ALK Positive Non-small Cell Lung Cancer × Thoracic × 30 days × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡